Following the success of immune checkpoint inhibitors (ICIs) in melanoma in 2010, multiple monoclonal antibodies against CTLA-4, PD-1, and programmed cell death 1 ligand 1(PD-L1) have been trialed and approved in solid tumors (4). Here, CD274 is linked to melanoma.